期刊文献+

雷珠单抗治疗新生血管型AMD无效病例的临床特征 被引量:1

Clinical analysis of invalid treatment of Ranibizumab intravitreal injection for choroidal neovascularization age-related macular degeneration
原文传递
导出
摘要 目的 研究玻璃体注射雷珠单抗(IVR)治疗新生血管型年龄相关性黄斑变性(AMD)无效病例的临床特征.方法 回顾性分析2012年3月至2014年12月在我院确诊为新生血管型AMD的106例(120只眼)病例资料.将患者分为两组,治疗有效组(A组)共79只眼;治疗无效组(B组)共41只眼.所有患者均接受前3个月每月1次IVR,后9个月按需注射治疗(PRN).分析患者的最佳矫正视力(BCVA),中央视网膜厚度(CRT),是否存在视网膜层间水肿(IRF)、视网膜下积液(SRF)、视网膜色素上皮脱离(PED),评价分析可能影响治疗效果的因素.结果 B组患者术后BCVA与术前相比差异无统计学意义(t =0.246,P>0.05).两组患者术后BCVA差异有统计学意义(t=0.569,P<0.05).B组患者的术后CRT,IRF,SRF,PED与术前相比,差异无统计学意义(t=0.937,0.736,0.672,0.639;P均>0.05).两组患者术后CRT,IRF,SRF,PED差异均有统计学意义(t =0.346,0.623,0.512,0.369;P均<0.05).BCVA与CRT,IRF,SRF,PED均呈负相关(r =-6.134,-2.458,-3.027,-4.268;P均<0.05).结论 IVR治疗新生血管型AMD无效的原因包括术前视力较差,发病时间较长,CNV靠近黄斑中心凹处,病灶范围较大,出现瘢痕化,CRT较厚,IRF水肿程度较重,SRF较多,并且有多处不规则PED. Objective To evaluate the clinical features of invalid treatment of Ranibizumab intravitreal injection (IVR) for choroidal neovascularization age-related macular degeneration.Methods Retrospective analysis of 106 cases (120 eyes) of choroidal neovascularization age-related macular degeneration was made between March 2012 and December 2014.All the patients were divided into two groups,effective group (group A) included 79 eyes;invalid group (group B) included 41 eyes.All the patients were performed IVR every month for the first three months and on demand in the last 9 months.The best corrected visual acuity (BCVA),central retinal thickness (CRT),and whether there was inner retinal fluid (IRF),subretinal fluid (SRF),and retinal pigment epithelium detachment (PED) were analyzed and evaluated the influence factor of efficacy.Results The BCVA in post-operation had no significant difference compared with that in pre-operation in group B (t =0.246,P 〉0.05).There were significant difference of BCVA between the two groups postoperatively (t =0.569,P 〈0.05).The CRT,IRF,SRF,PED in post-operation had no significant difference compared with that in pre-operation in group B (t =0.937,0.736,0.672,0.639;all P 〉0.05).There were significant difference of CRT,IRF,SRF,PED between the two groups postoperatively (t =0.346,0.623,0.512,0.369;all P 〈0.05).BCVA had negative correlation with CRT,IRF,SRF,PED (r =-6.134,-2.458,-3.027,-4.268;all P 〈0.05).Conclusions The reason of invalid treatment of IVR for neovascularization AMD include poor preoperative vision,long onset time,CNV close to fovea,large scope of lesions,scarring,thick CRT,heavy degree of IRF,much SRF,and multiple irregular PEDs.
作者 李琰 邵玲 杜敏 沈策英 闫淑 Li Yah;Shao Ling;Du Min;Shen Ceying;Yan Shu(The Second People's Hospital of Zhengzhou,Zhengzhou 450003,China)
出处 《中国实用眼科杂志》 2017年第8期817-820,共4页 Chinese Journal of Practical Ophthalmology
关键词 玻璃体注射雷珠单抗 新生血管 年龄相关性黄斑变性 治疗无效 Ranibizumab intravitreal injection Choroidal neovascularization Age-related macu-lar degeneration Invalid efficacy
  • 相关文献

参考文献7

二级参考文献31

  • 1Klein R,Klein BEK,Moss SE.The Wisconsin epidemiologic study ofdiabetic retinopathy IV:diabetic macular edema[J].Ophthalmology,1984,91(12):1464-1474.
  • 2Lehpamer,Brian.Subretinal fluid in uveitic macular edema:effect onVision and response to therapy [J].American Journal of ophthalmolo-gy ,2013,155(1);143-149.
  • 3Braithwaite,Nanji,AA,Greenberg,PB.Anti-vascular endothelialgrowth factor for macular edema secondary to central retinal vein oc-clusion[J].Cochrane Database of Systematic Reviews,2010,10(10):1002-1006.
  • 4Noma H,Funatsu H,Mimura T,et al.Increase of vascular endothelialgrowth factor and interleukin-6 in the aqueous humour of patientswith macular oedema and central retinal vein occlusion[J].Acta Oph-thalmol ,2009,88(6):646-651.
  • 5Flaxel Christina,Schain,Mitchell B,et al.Prospective randomizedcontrolled trial of combination Ranibizumab and Bromfenac(xi-brom)for Neovascular age-related macular degeneration a pilotStudy,Retina [J].The Journal of Retinal and Vitreous Disease,2012,32(3):417-423.
  • 6Rouvas Alexander,Petrou Petros,Ntouraki Amalia.IntravitrealRanibizumab for Branch Retinal Vein Occlucsion-induced MccularEdema nine-month Results of Prospective Study,Retina[J].The Jour-nal of Retinal and Vitreous Disease,2010,30(6):893-902.
  • 7Diabetic Retinopathy Clinical Research Network.A randomized trialcomparing intravitreal triamcinolone acetonide and focal grid photo-coagulation for diabetic macular edema [J].Ophthalmology,2008,115(9):1447-1459.
  • 8Peter Kroll,Eduardo BUchele Rodrigues,Steffen Hoerle.Pathogene-sis and Classification of Proliferative Diabetic Vitreoretinopathy [J],Ophthalmology,2007,221(2):2278-2294.
  • 9Nguyen GD,shah SM,Heier JS.READ-2 Study Group(2009)Pri-mary end point(six months)results of ranibizumab for edema of themAcuIa in diabetes(READ-2)study [J].Ophthalmology,2010,116(11):2175-2181.
  • 10Chun DW,Heier JS,Topping TM.A pilot study of multiple intravit-real injections of ranibizumab in patients with center-involvingclinically significant diabetic macular edema [J].Ophthalmology ,2006,137(2):313-22.

共引文献161

同被引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部